Search For
/
Stocks
Intraday Booster
Sector Booster
Stock Screener
Market Pulse
Screeners
More
Go Prime
My Plans
Privacy Policy
Contact
Refer & EarnScreenersMain
Stock Screener
Create Screener
Explore Screeners
Community ScreenersTrading Screeners
CandleSticks Screener
Top Gainers & Losers
Opening Range Breakout
Stock Screener AI
Stock Quality Scorecard
Overvalued StocksNewUndervalued StocksNewTechnical Screeners
NR4 Stocks
NR7 Stocks
Previous Day High Breakout
Previous Day Low Breakout
Previous Day Open Breakout
Bullish Crossover Stocks
Bearish Crossover Stocks
High Volume Shocker
VWAP Breakout Stocks
Range High Breakout
Range Low BreakoutMoreMarkets
Global Market Today
Global Indices
Indian Indices
NIfty TodayPrecious Metals
Gold Price TodayNew
Silver Price TodayNew
Platinum Price TodayNewSmart Money
FII DII DataNew
FII Buying
NSE Insider Trading
SLB Stocks DataDerivatives
FnO Movements
NSE F&O Lot Size
Ban ListAnalysis & Calendars
Technical DashboardSector Booster
Sector AnalysisNew
Result Calendar
Economic Calendar
Venus Remedies
Small Cap•1,187 Employees•IPO 1995
Current Price
₹967.40
34.1 (3.65%)Updated
Today's Range
923.45
₹967.40
975
52 Week Range
52W Low₹294.15
52W High₹1088.80
₹967.40
Downside228.88%
Upside12.55%
Price Chart
Compare with Peers
Historical Ratios
Track top 12 most important financial ratios
P/E Ratio: Price to Earnings - Most used valuation metric
Loading chart...
Analyzing Investment Quality
Processing 9 key metrics...
Key Metrics
Hover for details
Valuation
Market Cap
₹924.53 Cr
Market Cap
Total market value of companyP/E Ratio
13.15
P/E Ratio
Price to Earnings. Lower is generally better (<25 is good)P/B Ratio
0.99
P/B Ratio
Price to Book Value. <3 may indicate undervaluationEPS
₹52.61
EPS
Earnings Per Share. Higher and growing is positiveProfitability
ROE
7.12%
ROE
Return on Equity. >15% is good, >20% is excellentROCE
11.10%
ROCE
Return on Capital Employed. >15% is goodNet Margin
10.09%
Net Margin
Net profit as % of revenue. >10% is goodOperating Margin
-%
Operating Margin
Operating profit margin. >15% is goodGrowth
EPS Growth (5Y)
-%
EPS Growth (5Y)
5-year EPS growth. >15% is strongRevenue Growth (5Y)
13.81%
Revenue Growth (5Y)
5-year revenue growth. >10% is goodQtr Sales Growth
21.40%
Qtr Sales Growth
Quarter-over-quarter sales growthQtr Profit Growth
687.00%
Qtr Profit Growth
Quarter-over-quarter profit growthFinancial Health
Debt/Equity
-
Debt/Equity
Financial leverage. <1 is good, <0.5 is excellentBook Value
₹419.65
Book Value
Net asset value per shareDividend Yield
-%
Dividend Yield
Annual dividend as % of price. >2% is goodPromoter Holding
41.80%
Promoter Holding
Promoter stake. >50% shows confidenceGood
Average
Needs Attention
SWOT Analysis
Strengths
5 points- •Zero debt-to-equity ratio indicates strong financial stability and low leverage.
- •Exceptional quarterly profit growth of 687.00% reflects strong operational performance.
Weaknesses
5 points- •Relatively low ROE (4.64%) and ROCE (11.10%) indicate scope for efficiency.
- •Absence of dividend yield (0.00%) may deter income-focused investors.
Opportunities
5 points- •Growing global healthcare expenditure and demand for new treatments drive sector growth.
- •Focus on critical care segments like oncology and anti-infectives offers high growth.
Threats
4 points- •Intense competition from larger pharmaceutical players may limit market share.
- •Highly regulated pharmaceutical industry faces risks from adverse policy changes.
Segment-wise Financial Analysis
Fetching Financials...
Fetching Balance Sheet...
Fetching Cash Flow...
Shareholding Pattern
Loading shareholding data...
Company Insider Trading Activity
No insider trading data available
Corporate Action
Company Announcements
Technical Analysis & Indicators
Standard pivot points - most widely used
Pivot Points (CLASSIC)
| Level | Price | Distance | % Change |
|---|---|---|---|
| R4 | ₹1090.22 | +₹122.82 | +12.70% |
| R3 | ₹1038.67 | +₹71.27 | +7.37% |
| R2 | ₹1006.83 | +₹39.43 | +4.08% |
| R1 | ₹987.12 | +₹19.72 | +2.04% |
| PIVOT | ₹955.28 | -12.12 | -1.25% |
| CURRENT | ₹967.40 | - | - |
| S1 | ₹832.47 | -₹134.93 | -13.95% |
| S2 | ₹884.02 | -₹83.38 | -8.62% |
| S3 | ₹903.73 | -₹63.67 | -6.58% |
| S4 | ₹935.57 | -₹31.83 | -3.29% |
CPR Levels
Support
Resistance
S4
N/A
S3
N/A
S2
N/A
S1
N/A
| CPR |
BC: N/AP: N/ATC: N/A
R1
N/A
R2
N/A
R3
N/A
R4
N/A
LTP: N/A
PDH: N/A
PDL: N/A
● Market Sentiment
is trading CPR, indicating
● CPR Width
CPR is
● Opening Range
Day's range: ~
● Price Position
Trading Inside opening range
Delivery Volume Analysis & Trading Activity
Latest Volume-38.5% vs avg
0.40L
(30 Apr 2026)Delivery %-0.7% vs avg
64.3%
(30 Apr 2026)Avg Volume (20D)20-day average
0.65L
(01 Apr - 30 Apr)Avg Delivery %Trend ↓
65.0%
(01 Apr - 30 Apr)Delivery % indicates the percentage of traded volume that resulted in actual delivery. Higher delivery % (>50%) suggests genuine buying interest and stronger hands.
Peer Comparison & Industry Benchmarking
Quick Compare
Largest by Market Cap
Sun Pharmaceutical Industries Ltd
4.12L ₹ Cr
Best Profit Growth
Ind-Swift Laboratories Ltd
833.00 %
Highest Dividend Yield
Sun Pharmaceutical Industries Ltd
0.91 %
Peer Comparison
| Company Name |
|---|
 Albert David Ltd |
 Ind-Swift Laboratories Ltd |
 Kilitch Drugs (India) Ltd |
 Medicamen Biotech Ltd |
 Sun Pharmaceutical Industries Ltd |
 Valiant Laboratories Ltd |
About
Venus Remedies Ltd
Venus Remedies Limited is a pharmaceutical company headquartered in Panchkula, India, operating both domestically and internationally. Their core business revolves around the research, development, manufacturing, and distribution of a wide array of pharmaceutical products.
The company's product portfolio spans a diverse range of therapeutic areas, catering to a broad spectrum of medical needs. These therapeutic areas include, but are not limited to: analgesics (pain relievers), antipyretics (fever reducers), anti-diabetics, antibiotics, antiemetics (anti-nausea medications), antivirals, cardiovascular medications, disinfectants and antiseptics, gastrointestinal therapies, hepatoprotective agents (liver protectants), hormone therapies, immunostimulants, iron supplements, muscle relaxants, neurological medications, oncology medications, respiratory medications, and anticoagulants (blood thinners).
Beyond conventional pharmaceuticals, Venus Remedies also maintains a significant presence in the herbal medicine market, offering a portfolio of products derived from natural sources. This demonstrates a commitment to providing diverse treatment options and potentially catering to a broader consumer base interested in alternative or complementary therapies.
Established in 1989, Venus Remedies has a history of nearly three and a half decades in the pharmaceutical industry. This longevity suggests a degree of stability and market experience, although the specific details of their market share and financial performance would require further information beyond the provided text.
In summary, Venus Remedies' business model is built upon a diversified product portfolio encompassing both conventional and herbal pharmaceuticals, targeting a wide array of therapeutic areas and serving both domestic and international markets. Their long operational history suggests established processes and infrastructure within the pharmaceutical industry.
COMPANY FACTS - VENUSREM
Registered Address
51-52, Industrial Area, Phase-1
Panchkula
HARYANA
IN
Tel: 911722933090
Website:https://www.venusremedies.com/
Investor Relations:https://venusremedies.com/investorrelation
Company Details
Group: Pharmaceuticals, Biotechnology & Life Sciences
Sector: Health Care
Industry: Pharmaceuticals
Exchange: NATIONAL STOCK EXCHANGE OF INDIA
Employees: 1,187
IPO Date: 15/02/1995
Investor Questions Answered
Venus Remedies Ltd (VENUSREM) Stock FAQs
Get answers to the most common questions about Venus Remedies Ltd stock price, fundamentals, financial metrics, and investment analysis
The current share price of Venus Remedies Ltd (VENUSREM) is ₹967.4. Today, the stock has gained by ₹34.10 (3.65%), trading in a range of ₹923.45 to ₹975. The stock opened at ₹933.45 with a trading volume of 40,239 shares.
Venus Remedies Ltd can be considered for long-term investment based on several factors. The company has a market capitalization of ₹924.53 crores, P/E ratio of 13.15, ROE of 7.12%, and ROCE of 11.10%. The dividend yield stands at 0.00%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
The 52-week high price of Venus Remedies Ltd (VENUSREM) is ₹1,088.8, while the 52-week low is ₹294.15. Currently trading at ₹967.4, the stock is 84.7% away from its 52-week low and 11.1% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
Whether to buy Venus Remedies Ltd stock at ₹967.4 depends on multiple factors. The stock is currently trading with a P/E ratio of 13.15 and P/B ratio of N/A. Today's performance shows a gain of 3.65%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
Venus Remedies Ltd offers a dividend yield of 0.00%, which means for every ₹100 invested at the current price of ₹967.4, you can expect to receive approximately ₹0.00 annually as dividends. The face value of the stock is ₹10.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
Venus Remedies Ltd's key financial metrics include: P/E Ratio: 13.15, P/B Ratio: N/A, ROE: 7.12%, ROCE: 11.10%, Dividend Yield: 0.00%, EPS: ₹52.61, Book Value: ₹419.65, Debt-to-Equity: 0.00, and Current Ratio: N/A. The company's market cap stands at ₹924.53 crores. These metrics help evaluate the company's valuation, profitability, and financial health.
Venus Remedies Ltd stock opened at ₹933.45 and is currently trading at ₹967.4, showing a gain of ₹34.10 (3.65%). The intraday high is ₹975 and low is ₹923.45. The trading volume stands at 40,239 shares, indicating moderate market participation today.
Venus Remedies Ltd has a Price-to-Earnings (P/E) ratio of 13.15, which means investors are willing to pay ₹13.15 for every ₹1 of earnings. With an EPS of ₹52.61, this P/E ratio suggests the stock may be undervalued or facing growth challenges. Compare this with industry peers and historical P/E ratios for better context.
Venus Remedies Ltd has a market capitalization of ₹924.53 crores, making it a small-cap company. Market cap is calculated by multiplying the current stock price (₹967.4) by the total number of outstanding shares. This metric helps investors understand the company's size, stability, and investment risk profile.
Venus Remedies Ltd has a book value of ₹419.65 per share and a Price-to-Book (P/B) ratio of N/A. The current market price is ₹967.4, which is 130.5% above the book value. A P/B ratio below 1 may indicate undervaluation or asset quality concerns.
Venus Remedies Ltd has a Return on Equity (ROE) of 7.12% and Return on Capital Employed (ROCE) of 11.10%. ROE measures how efficiently the company generates profits from shareholders' equity, while ROCE indicates how well the company uses its capital to generate profits. These returns may need improvement for better profitability. Higher percentages generally indicate better financial performance.
Venus Remedies Ltd operates in the diversified sector and belongs to the general industry. The company competes with other players in this space and its performance is influenced by sector-specific trends, regulatory changes, and market dynamics. Understanding the sector helps investors assess growth potential, cyclical patterns, and industry-specific risks that may impact the stock's performance.
Venus Remedies Ltd has a debt-to-equity ratio of 0.00, which measures the company's financial leverage by comparing total debt to shareholders' equity. A low ratio suggests conservative financing with minimal debt. Lower ratios generally indicate lower financial risk, but optimal levels vary by industry.
Venus Remedies Ltd has an Earnings Per Share (EPS) of ₹52.61, which represents the company's profit allocated to each outstanding share. With a current stock price of ₹967.4 and P/E ratio of 13.15, investors are paying 13.15 times the annual earnings per share. This strong EPS indicates robust profitability. Track EPS growth over quarters to assess earnings momentum.
Venus Remedies Ltd has reported a sales growth of N/A% and profit growth of N/A%. The company may be facing growth challenges or operating in a mature market. Consistent growth over multiple quarters is a positive indicator for long-term investors. Compare these growth rates with industry peers for better perspective.
Venus Remedies Ltd has a current ratio of N/A, which measures the company's ability to pay short-term obligations with current assets. A ratio below 1 may indicate potential liquidity concerns. This metric is crucial for assessing the company's working capital management and financial safety.
To analyze Venus Remedies Ltd stock, consider: 1) Fundamental Analysis - Review P/E (13.15), ROE (7.12%), debt-to-equity (0.00), and growth rates. 2) Technical Analysis - Check 52-week range (₹294.15 - ₹1088.80), moving averages, and chart patterns. 3) Valuation - Compare current price (₹967.40) with book value (₹419.65) and industry peers. 4) Financial Health - Assess current ratio (N/A) and cash flows. 5) Growth Prospects - Evaluate sales growth (N/A%) and profit growth (N/A%). Always diversify and consult a financial advisor.
The face value (or par value) of Venus Remedies Ltd share is ₹10.00. Face value is the nominal value of a share as stated in the company's charter and is used for accounting purposes and calculating dividends. The current market price of ₹967.4 is 9574x the face value. Face value remains constant unless the company undergoes a stock split or bonus issue, while market price fluctuates based on demand and supply.
Investing in Venus Remedies Ltd carries several risks: 1) Market Risk - Stock price volatility (52-week range: ₹294.15 - ₹1088.80). 2) Business Risk - Industry-specific challenges in the sector. 3) Financial Risk - Debt-to-equity ratio of 0.00 indicates leverage. 4) Liquidity Risk - Based on trading volume of 40,239 shares. 5) Valuation Risk - P/E of 13.15 may indicate over/undervaluation. 6) Economic Risk - Macroeconomic factors affecting the industry. Diversify your portfolio and invest only what you can afford to lose.
Venus Remedies Ltd operates in the industry with key metrics: P/E ratio of 13.15, ROE of 7.12%, market cap of ₹924.53 crores, and dividend yield of 0.00%. To make an informed comparison, analyze these metrics against industry peers considering factors like revenue growth (N/A%), profit margins, debt levels (D/E: 0.00), and market position. Use our peer comparison tool on this page to see detailed side-by-side analysis with competitors.
Target prices for Venus Remedies Ltd vary among analysts and depend on multiple factors including earnings projections, industry trends, and market conditions. The stock is currently trading at ₹967.4, with a 52-week range of ₹294.15 to ₹1088.80. Based on fundamentals like P/E (13.15), ROE (7.12%), and growth rates, analysts may have different target prices. Always refer to recent research reports from reputed brokerages and make decisions based on your own analysis and risk appetite.
Consider selling Venus Remedies Ltd stock when: 1) Target Price Achieved - If the stock reaches your predetermined target from current ₹967.40. 2) Fundamental Deterioration - Declining ROE (currently 7.12%), increasing debt (D/E: 0.00), or falling growth rates. 3) Better Opportunities - Finding stocks with superior risk-reward ratios. 4) Portfolio Rebalancing - When the stock becomes overweight in your portfolio. 5) Changed Investment Thesis - If reasons for buying no longer hold. 6) Stop Loss - If price falls below your risk threshold. Always base decisions on thorough analysis rather than emotions.
Tax implications for Venus Remedies Ltd stock investments: 1) Short-term Capital Gains (STCG) - If sold within 1 year, gains taxed at 15% plus cess. 2) Long-term Capital Gains (LTCG) - If held over 1 year, gains above ₹1 lakh taxed at 10% without indexation. 3) Dividend Income - Dividends (current yield: 0.00%) are taxable as per your income tax slab. 4) Securities Transaction Tax (STT) - Applicable on both buy and sell transactions. 5) Intraday Trading - Treated as speculative income, taxed as per slab. Tax laws change periodically, so consult a tax advisor for personalized guidance and latest regulations.
Menu